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Abstract 
Endurance exercise is an established cause of cardiac troponin (cTn) elevation, of further 
interest is whether this rise represents clinical significance.  This study compared cTnT rise 
in three cohorts of marathon runners using a high sensitivity assay; control runners, those 
with known heart disease and runners who collapsed at the finish line. Control runners (n = 
126) and runners with heart disease (n = 12) were prospectively recruited with cTnT levels 
measured pre-race and at race completion. Collapsed runners (n = 15) were retrospectively 
recruited. A mixed model ANCOVA was used to compare the three groups. Pre-race median 
cTnT for the control group and heart disease groups were 3.9 ng.L-1 (IQR 3.1 ng.L-1) and 4.1 
ng.L-1 (IQR 3.4 ng.L-1). Post-race values for the three groups were; control 45.6 ng.L-1 (IQR 
42.5 ng.L-1),  heart disease 41.2 ng.L-1 (IQR 36.1 ng.L-1) and collapsed 41.9 ng.L-1 (IQR 57.8 
ng.L-1). Post-race cTnT and cTnT change were significantly correlated with pre-race cTnT 
within the control group (r = 0.38 and 0.30, p < 0.01). There was no difference in post-race 
cTnT (adjusted for pre-race cTnT) between the three groups. None of the runners reported 
symptoms suggestive of acute myocardial infarction on follow up.  These results 
demonstrate that marathon running is associated with an asymptomatic cTnT rise for all 
runners and this rise is significantly correlated to baseline cTnT levels, in addition, marathon 
runners with pre-existing cardiac pathology or who collapse at the finish line do not exhibit 
an increased cTnT rise compared to healthy runners.  
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1. Introduction
The association between endurance exercise and acutely raised cardiac troponin (cTn) is 
well established, with post-exercise cTn levels observed that meet the biochemical criteria 
for acute myocardial infarction (MI) (1,2). The kinetics of post-exercise cTn rise do not 
however match that of acute MI, with normalisation within 24-48 hours (3,4), as opposed to 
7-10 days (5). A comparable transient acute cTn rise of similar kinetics to exercise 
associated troponin elevation is exhibited in pathological conditions that involve increased 
physiological stress and/or increased cardiac workload (e.g. acute heart failure, myocarditis, 
pericarditis, pulmonary embolism and sepsis) (5). These conditions are thought to represent 
myocardial stress but through mechanisms that are not sufficiently severe to cause the 
significant cellular necrosis exhibited in myocardial infarction. Such damage has been 
termed myocardial injury and is thought to be caused by factors such as subcritical 
ischaemia, increased chamber wall stress, oxidative stress and inflammatory processes 
(6,7). The mechanism and clinical significance underlying cTn elevation following exercise 
remains under investigation and it is yet to be determined if the rise exhibited represents a 
benign process or if there are associated negative health consequences (1).   
The cTn complex is composed of three protein molecules (cTnC, cTnI and cTnT), cTnI or 
cTnT are measured in clinical practice to quantify cTn elevation. Four prior studies have 
investigated cTnT rise in a field of healthy marathon runners using the Roche Elecsys fifth 
generation high-sensitivity cTnT assay that is in common diagnostic use (4,8–10), with all 
studies demonstrating rise from a pre-race baseline. There has been considerable inter-
individual variation in the degree of cTnT rise, with no runner characteristic consistently 
correlated and there is no established explanation for the variation. Baker et al. (10) explored 
cTnT changes in a control group of healthy runners (n = 57), runners with known heart 
disease (HD) and runners who collapsed at the finish line, with a with a hypothesis that 
runners with underlying HD or who collapse will experience greater myocardial stress and 
therefore exhibit higher post-race cTnT levels. No significant difference was found between 
the three runner groups, although small number of runners with HD (n = 5) and collapsed 
runners (n = 14) were included.  
This study expands on prior studies investigating cTnT rise in marathon running using a 
larger cohort of healthy runners, establishing the most comprehensive reference range to 
date for marathon associated cTnT increase and thus provides a more robust comparison of 
cTnT levels in healthy runners, HD runners and collapsed runners.  
2. Materials and Method
2.1 Participants 
The study recruited runners at the 2017 Brighton Marathon (9th April 2017). One hundred 
and thirty five runners were recruited to the control (CON) group (eighty two males, fifty three 
females), fifteen into the HD group (nine males, six females) and fifteen into the collapsed 
(COL) group (twelve males, three females). Runners were prospectively recruited into the 
CON or HD group with advertising to all marathon entrants via email and also through social 
media channels. All runners were eligible for enrolment into the CON group providing they 
did not meet the inclusion criteria for the HD or COL group. The inclusion criteria for HD was 
defined as a self-reported history of valvular heart disease, atrial fibrillation, ischaemic heart 
disease, cardiomyopathy, transplanted heart and/or hypertension with left ventricular 
hypertrophy. The COL group of runners were retrospectively recruited at the finish line 
medical tent. Collapse was defined as those runners unable to stand unaided upon 
completing the marathon (11) and who required emergency medical treatment involving 
diagnostic biochemistry tests.  
All study participants provided written informed consent and institutional ethical approval 
(SSCERC 0217) was issued by the University of Brighton in accordance with the Helsinki 
declaration 1975 (revised 2008).  
2.2 Study Design 
At the pre-race exhibition occurring on the two days prior to the marathon, the CON and HD 
runners attended the research stall.  A venous blood sample was taken and a questionnaire 
on their anthropometrics, health and training history completed. Following marathon 
completion the CON and HD runners presented to the finish line medical tent where a further 
venous blood sample was taken within ten minutes of marathon completion. All 
venepuncture was performed at the antecubital fossa in a seated position, 5 ml blood was 
collected into a Vacuette  Z Serum Separator Clot Activator tube (Greiner Bio-One 
International, Austria) tube using a 21G Vacuette needle (Greiner Bio-One International, 
Austria). Blood was analysed within four hours of collection using an 
electrochemiluminescence fifth generation high-sensitivity cTnT assay (Elecsys, Roche 
Modular E170; Roche, Basel, Switzerland) (7). This had a limit of blank of 3ng.L-1, limit of 
detection of 5ng.L-1, upper limit of normal based on the 99th percentile of 14ng.L-1, coefficient 
of variation at URL of <8%.  Recruited runners that failed to finish or who provided a 
haemolysed blood sample were excluded from the analysis.  
All runners were asked about symptoms suggestive of acute MI upon marathon completion 
and provided with an information leaflet regarding post-race symptoms that should prompt 
urgent self-referral for medical assessment. The European Society of Cardiology 2015 
biochemical diagnostic threshold for MI of a cTnT rise from baseline of > 5 ng.L-1 when using 
the Elecsys cTnT assay (2) was noted, however given the high frequency of post-exercise 
cTnT elevations in prior studies only those runners who reported symptoms suggestive of 
acute MI or who had a post-race cTnT over 50 ng.L-1 were proactively followed up. The 50 
ng.L-1  threshold was adopted given the noted low positive predictive value of such 
elevations in diagnosing the likelihood of acute MI (2,12,13).  
The medical treatment of runners who collapsed at the finish line was supervised by a 
Consultant from Emergency Medicine or Anaesthetics. Diagnostic tests performed on these 
runners included intravenous access and blood sampling for point of care blood glucose and 
electrolyte assessment. At the time of the diagnostic blood tests an additional 5 ml of blood 
was collected in a Vacuette  Z Serum Separator Clot Activator tube (Greiner Bio-One 
International, Austria). This blood was analysed for cTnT if the runner subsequently 
consented for enrolment into the study following their recovery. Mechanism of collapse was 
established from review of the medical notes.  
2.3 Statistical Analysis 
Data was assessed for normality and sphericity and adjusted where necessary using the 
Huynh-Feldt method. Troponin measurements below the limit of blank (<3ng.L-1) were 
assigned a value of 3 ng.L-1, values between the limit of blank and limit of detection (3 to 5 
ng.L-1) were used in the analysis. Both Pearson’s or Spearman’s rank correlation were used 
where appropriate to determine the relationship between baseline anthropometrics, training 
history, marathon experience, finishing time and baseline cTnT (where available) with cTnT 
change. A mixed model ANCOVA was used to assess the pre and post-race cTnT between 
the CON and HD groups with the only covariate in the model being the pre-race cTnT (as no 
other variables had strong and significant correlations). An additional ANCOVA was 
performed including the COL group using the CON group pre-race median as an estimated 
pre-race median for the COL group. All statistical tests were completed using SPSS 
Statistics 22 (IBM, New York). The alpha level was set at 0.05. Values are reported as mean 
or median with standard deviation (SD) or interquartile range (IQR) unless otherwise 
indicated. 
3. Results
Baseline anthropometrics, training history and marathon experience for the included runners 
are reported in table 1. Nine CON runners were excluded (7%); seven runners failed to finish 
and two blood samples haemolysed. Three HD runners failed to finish and were excluded. 
Therefore, one hundred and twenty six CON runners and twelve COL runners were included 
in the primary analysis. The proportion of runners who failed to finish race amongst the 
entire marathon population was 8%. Within the included twelve HD runners there were six 
with valvular disease, three with paroxysmal cardiac arrhythmias, two with ischaemic heart 
disease and one with a closed patent foramen ovale (endovascular repair).  
Fifteen COL runners were recruited, with a variety of collapse aetiology; seven cases of 
hyperthermia (core temperature > 38.5oC), four cases of exhaustion, two cases of 
hypoglycaemia, two cases of dehydration and one case of hypothermia (core temperature < 
35.0 oC). None of the COL runners had a history of cardiovascular disease. Eighteen 
marathon runners collapsed prior to the marathon completion and required diagnostic 
biochemistry (eight cases of hyperthermia, two cases of hypothermia, two cases of 
hypoglycaemia, three cases of dehydration, three cases with unknown aetiology) however 
these were not considered appropriate for inclusion within the study due to the variable 
workload completed at time of collapse. 
Weather conditions over the day of the marathon were unusually hot and sunny for the UK in 
April (18-23°C, 40-50% relative humidity). 
Table 1 details marathon finishing time and cTnT data for the three groups. Seven runners in 
the CON group had a pre-race cTnT above the upper reference limit of 14 ng.L-1 with no 
runners in the HD group having a pre-race cTnT above 14 ng.L-1. All runners had a cTnT 
rise from baseline with 12/12 HD runners and 123/126 CON runners exhibiting a post-
race 
cTnT above the 99th percentile value of 14 ng.L-1. None of the runners reported post race 
symptoms suggestive of acute MI and none of the runners with a post-race cTnT > 50 ng.L-1 
reported any symptoms on follow up that warranted further medical assessment.  
No significant or strong (r > 0.3) correlations were found between baseline anthropometrics, 
training history, marathon experience or marathon completion time and post-race cTnT or 
cTnT change (Δ cTnT) for the CON group. Pre-race cTnT was significantly correlated with 
post-race cTnT (r = 0.38, p < 0.01) and Δ cTnT (r = 0.30, p < 0.01) (table 1). There was no 
difference in post-race cTnT (adjusted for pre-race cTnT) between the CON and HD 
groups (F = 0.026, df = 1, p = 0.873) and CON, HD and COL groups using the estimated 
pre-race COL cTnT value of 5.4 ng.L-1 (F = 0.015, df = 2, p = 0.985). 
4. Discussion
This study is the largest study to date investigating cTnT rise in marathon running using the 
Roche Elecsys fifth generation high sensitivity cTnT assay that is in common medical 
diagnostic usage. It also incorporates the largest number of runners with heart disease or 
who collapsed at the finish line as a means of investigating the clinical significance of cTnT 
rise. The results provides compelling evidence that marathon running always causes a rise 
in cTnT; and that the magnitude of this rise, while variable, is almost always likely to result in 
a cTnT level required for the biochemical diagnosis of acute MI. However, the results also 
demonstrate no difference in cTnT rise when compared across the CON, HD and COL 
groups (figure 1) with a similar marathon finishing time across the three groups (table 1).  
Four prior studies have investigated cTnT rise in marathon runners utilising the same high-
sensitivity cTnT assay with an average post-marathon value of between 31.1 to 47.0 ng.L-1 
(4,8–10). The median cTnT rise of 45.6 ng.L-1 observed in the CON group is at the higher 
end of the range seen in prior studies. Peak post-exercise cTnT value is not achieved 
immediately upon exercise completion with peak post-exercise cTnT and cTnI values 
reported 1-4 hours following exercise completion (14,15). As our study was sampled closer 
to race completion than previous studies, the higher cTnT rise exhibited is unlikely related to 
differences in sample timing. Of note the 2017 Brighton Marathon conditions were 
unseasonably warm and the majority of runners would not have been acclimatised for such 
conditions. Un-acclimatised runners are known to be less tolerant of higher 
temperatures 
with comparatively reduced thermoregulation mechanisms and therefore experiencing a 
greater physiological strain and increased cardiac workload when exercising in unfamiliarly 
warm temperatures (16,17). The literature exploring the effect of exercise temperature on 
cTnT is limited to a single study; Shave et al. performed 100 mile cycling trials in 0oC and 
19oC temperatures on 8 highly trained male athletes, 2 of the athletes in the 19oC condition 
demonstrated a measurable post-exercise cTnT level but none at 0oC (18). It is likely that 
exercising temperature has some influence on TnT rise given its contribution to the 
physiological stress of exercise, however further research is required to establish this 
potential relationship.  
The lack of strong and significant correlations between baseline anthropometrics, training 
history, marathon experience or marathon completion time and cTn rise is in contrast to 
earlier smaller studies investigating cTn rise and exercise. These studies have identified 
associations with younger age (19,20), endurance exercise inexperience (21,22), endurance 
exercise experience (8) marathon intensity (23) and marathon time (4,20) with cTn rise. 
However no variables have been consistently correlated with cTn rise across a number of 
studies and there remains no consensus regarding predictors of cTn rise despite significant 
variation between individuals (1). The observation that baseline cTnT was correlated to post-
race cTnT is in agreement with an earlier marathon study (9) and laboratory based exercise 
trials (24,25). In addition, our study identified a correlation between baseline cTnT and the 
magnitude of exercise associated cTnT increase (Δ cTnT).  Given the recent work 
demonstrating an association between baseline cTnI and future cardiovascular events in 
healthy individuals (26,27), it may be that these baseline and post exercise cTnT 
associations reflect a predisposition to  future cardiac disease or existing subclinical cardiac 
pathology.   
Our data indicates that there is no difference in cTnT rise between healthy marathon 
runners, those with HD or COL runners. This finding is in agreement with the only other 
study assessing these populations (10). Although only a relatively small number of HD 
runners were recruited, the cohort represented a diverse spectrum of HD pathology. The 
similarity of the cTnT rise with the CON runners demonstrates that variations in post-
marathon cTnT rise cannot be used to reliably identify individuals with undiagnosed cardiac 
abnormalities. There was also no difference in post-race cTnT values between CON and 
COL runners, suggesting that post-marathon cTnT rise is not influenced by increased 
physiological stress.   Of useful clinical note is the similar distribution of cTnT rise exhibited 
across the CON and COL groups, suggesting that collapsed runners, who do not present 
with a clinical suspicion of cardiac pathology, are not sustaining significant occult myocardial 
injury.   
The small numbers of HD and COL runners and the heterogeneous nature of the HD group 
primarily limit the study. The self-reported selection criteria is a pragmatic approach to recruit 
marathon runners with HD.  Unfortunately, we are unaware of any published databases of 
the incidence of HD within mass participation marathon events to establish if the recruited 
cohort of HD runners within this study is representative of the spectrum of HD pathology 
found amongst marathon runners. The pre-race cTnT was comparable between the CON 
and HD runners suggesting that the clinical severity of disease amongst the HD runners was 
relatively low. Increased understanding of the functional impact that exercise and 
cardiovascular disease imposes on the runner, with for example pre and post-marathon 
echocardiography, blood pressure monitoring and electrocardiography, would benefit future 
work comparing cTn rise in healthy vs HD runners. The small number of collapsed runners 
recruited in this study reflects the low incidence of marathon finish line collapse that requires 
diagnostic biochemistry as part of the initial medical management, expanding the numbers in 
this cohort would require an aggregate analysis of cTnT changes in collapsed runners 
across a number of marathons.   
5. Perspective
This study demonstrated a quantifiable and variable cTnT rise in a diverse population of 
marathon runners with no difference between a healthy control group, a group with heart 
disease and a group that collapsed at the finish line. This work supports the existing 
literature and consensus that exercise induced cTn rise does not represent significant 
myocardial necrosis given the asymptomatic nature of the rise, however the question of what 
influences the variable rise observed between individuals and if there is associated clinical 
significance remains. If cTnT rise is related to myocardial cell injury or myocardial cell stress, 
then the correlation with baseline cTnT and post-marathon cTnT rise is of note given the 
recent work associating baseline cTnI with future cardiac events. The long-term prognostic 
significance of exercise induced cTn rise is a novel perspective that warrants further 
investigation. 
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Table 1: High-sensitivity cTnT values for CON, HD and COL runners. Anthropometric, training 
history and marathon experience for CON correlated to troponin change from baseline and post-
marathon. Mean or median and standard deviation (SD) or interquartile range (IQR). * indicates 
statistical significance (p < 0.01). 
CON 
(n = 126) 
HD 
(n = 12) 
COL 
(n =15) 
Mean (SD) 
Correlation 
with post- 
cTnT (r) 
Correlation 
with Δ cTnT 
(r) 
Mean (SD) Mean (SD) 
Age (year) 40 (11) 0.01 -0.02 46 (9) 42 (12) 
Height (m) 1.72 (0.09) 0.12 0.04 1.73 (0.09) 1.78 (0.05) 
Body mass (kg) 73.9 (11.8) 0.04 0.11 73.4 (16.2) 79.1 (9.4) 
Previous marathons completed 7 (17) -0.25* - 0.26* 3 (3) 2 (3) 
Mean weekly running distance in 
previous 12 weeks (km) 
42.6 (20.1) 0.06 0.05 56.4 (23.7) 40.6 (12.9) 
an training velocity (km.hr
-1
) 10.7 (1.7) 0.02 0.02 9.6 (0.8) 10.7 (1.3) 
Marathon time (min) 274 (56) - 0.08 - 0.09 274 (34) 280 (72) 
rathon velocity (km.hr
-1
) 9.6 (2.0) -0.08 - 0.09 9.4 (1.1) 9.4 (1.8) 
Median 
(IQR) 
Correlation 
with post- 
cTnT (r) 
Correlation 
with Δ cTnT 
(r) 
Median (IQR) 
Median 
(IQR) 
-race cTnT (ng.L
-1
) 3.9 (3.1) 0.38* 0.30* 4.1 (3.4) 
t-race cTnT (ng.L
-1
) 45.6 (42.5) 41.2 (36.1) 41.9 (57.8) 
TnT (ng.L
-1
) 40.8 (42.3) 35.1 (35.4) 
% Δ cTnT 1010 (1144) 803 (1112) 
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Figure 1: Box plots demonstrating high-sensitivity cTnT values pre-marathon for CON and 
HD runners (top) and post-marathon cTnT values for CON, HD and COL runners (bottom). 
